ClinicalTrials.gg
CompletedNCT02266524Updated Oct 17, 2014

Pharmacokinetics, Safety and Tolerability of Tamsulosin Hydrochloride in Children With Voiding Disorders

A Phase 1 interventional study of Tamsulosin hydrochloride, very low dose and Tamsulosin hydrochloride, low dose in Urination Disorders, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 5 Years to 15 Years. Per ClinicalTrials.gov, last updated 2014-10-17.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
5 Years to 15 Years
Sex
All
01

Study summary

To investigate pharmacokinetics, safety, and tolerability of tamsulosin hydrochloride in children with voiding disorders

02

Conditions studied

  • Urination Disorders

Browse trials for

03

In context

Urination Disorders

25 studies on the registry are indexed under Urination Disorders; 5 are open to participants now.

This study's enrollment of 48 is below the median of 113 across 19 interventional studies indexed under Urination Disorders.

Browse Urination Disorders studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Boys and girls with (or a history of) voiding disorders
  • Age: 5 to 15 years
  • Body weight and height ≥ 5 % and ≤95 % of normal using nomograms
  • Signed and dated written by the parent or guardian and, where appropriate, informed assent by the child, prior to admission into the study in accordance with good clinical practice (GCP) and the local legislation, has been obtained

Exclusion criteria

Exclusion Criteria:

  • abnormalities found at, or before randomization at Visit 2 [i.e., abnormal: vital signs (e.g., hypotension), ECGs, as well as significant findings during the physical examination], as determined by the investigator
  • Clinically relevant conditions including, but not limited to, the following: gastrointestinal, cardiovascular (e.g., subjects that fall above the 90th percentile according to the blood pressure nomogram in the ISF), hepatic, renal, hematologic, metabolic (including diabetes mellitus), immunological, hormonal disorders, respiratory disease or cancer
  • Subjects who had surgery within the last 30 days
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • Subjects that have a neurological impairment or psychiatric disorder that prevents their comprehension of consent and their ability to comply with the protocol
  • History of relevant orthostatic hypotension, fainting spells or blackouts. Postdural symptoms occurring (e.g., lightheadedness, dizziness, and fainting) with or without a change in blood pressure and / or pulse rate within 6 weeks of Visit 2
  • Relevant acute infections, especially with regards to urinary tract infections or active genitourinary infection
  • History of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Subjects with known hypersensitivity to FLOMAX® (tamsulosin hydrochloride) or other alpha-blockers
  • Use of medications classified as cytochrome P450 3A4 () inhibitors and inducers within 10 days prior to administration of trial drug
  • Intake of drugs with a long half-life (> 24 hours) within less than 10 half-lives of the respective drug prior to administration
  • Participation in another trial with an drug within 1 month prior to administration or during the trial
  • Inability to comply with dietary regimen of study center
  • Pregnancy or subjects that are breast feeding
  • All subjects parents and guardians in the investigator's opinion who cannot understand the terms of the form and subject information
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Tamsulosin hydrochloride, very low dose

    Drug: Tamsulosin hydrochloride, very low dose

  • Experimental
    Tamsulosin hydrochloride, low dose

    Drug: Tamsulosin hydrochloride, low dose

  • Experimental
    Tamsulosin hydrochloride, medium dose

    Drug: Tamsulosin hydrochloride, medium dose

  • Experimental
    Tamsulosin hydrochloride, high dose

    Drug: Tamsulosin hydrochloride, high dose

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum concentration of the analyte in plasma (Cmax)

    Time frame: Up to 26 hours after drug administration

  2. Time from dosing to maximum concentration of the analyte in plasma (tmax)

    Time frame: Up to 26 hours after drug administration

  3. Area under the concentration-time curve of the analyte in plasma (AUC)

    Time frame: Up to 26 hours after drug administration

  4. Percentage of the AUC0-∞ that is obtained by extrapolation (%AUCtz-∞)

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after single-dose administration (AUC0-∞)

    Time frame: Up to 26 hours after drug administration

  5. Terminal rate constant of the analyte in plasma (λz)

    Time frame: Up to 26 hours after drug administration

  6. Terminal half-life of the analyte in plasma (t1/2)

    Time frame: Up to 26 hours after drug administration

  7. Mean residence time of the analyte in the body after po administration (MRTpo)

    Time frame: Up to 26 hours after drug administration

  8. Apparent clearance of the analyte in the plasma after extravascular administration (CL/F)

    Time frame: Up to 26 hours after drug administration

  9. Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)

    Time frame: Up to 26 hours after drug administration

  10. Weight-normalized Cmax

    Time frame: Up to 26 hours after drug administration

  11. Weight-normalized AUC0-∞

    Time frame: Up to 26 hours after drug administration

  12. Weight-normalized (AUC0-tz)

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration after single-dose administration (AUC0-tz)

    Time frame: Up to 26 hours after drug administration

Secondary outcomes

  1. Number of patients with clinically relevant changes in physical examination

    Time frame: Pre-dose, up to 26 hours after drug administration

  2. Number of patients with clinically relevant changes in vital signs (blood pressure, pulse rate, respiratory rate)

    Time frame: Pre-dose, up to 26 hours after drug administration

  3. Number of patients with clinically relevant changes from baseline in orthostatic test

    Time frame: Pre-dose and 4 hours after drug administration

  4. Number of patients with clinically relevant changes in 12-lead ECG

    Time frame: Pre-dose, up to 26 hours after drug administration

  5. Number of patients with clinically relevant changes from baseline in laboratory tests

    Time frame: Pre-dose and 26 hours after drug administration

  6. Number of patients with adverse events

    Time frame: Up to 7 days after drug administration

  7. Global assessment of tolerability by the investigator on a 5-point rating scale

    Time frame: 26 hours after drug administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005 and a primary completion of Apr 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2014
First posted
Oct 17, 2014
Start
Jan 2005
Primary completionActual
Apr 2005
Last update
Oct 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02266524
Responsible party
Sponsor
First posted
Oct 17, 2014
Start date
Jan 2005
Primary completion
Apr 2005
Last update
Oct 17, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion